Skip to main content

Table 1 Probability of hospitalization, excess mortality for hospitalized states and probability of adverse events

From: An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany

Parameter Value Variance Distribution and coefficients for probabilistic sensitivity analysis Source
Six-month probability of excess mortality for NYHA class II 0.04 0.032–0.048 Beta (α = 4; β = 96) Cowper 2004 [35]
Six-month probability of excess mortality for NYHA class III 0.07 0.056–0.084 Beta (α = 7; β = 93)
Six-month probability of excess mortality for NYHA class IV 0.28 0.224–0.336 Beta (α = 28; β = 72)
Monthly probability of hospitalization for NYHA class I 0.015 0.008–0.023 Beta (α = 1.5; β = 98.5) Ford 2012 [19]
Monthly probability of hospitalization for NYHA class II 0.024 0.012–0.036 Beta (α = 2.4; β = 97.6)
Monthly probability of hospitalization for NYHA class III 0.024 0.012–0.036 Beta (α = 2.4; β = 97.6)
Monthly probability of hospitalization for NYHA class IV 0.154 0.77–0.23 Beta (α = 15.4; β = 84.6)
Probability of short-term adverse events (30 days) 0.070 0.03–0.1 Beta (α = 3; β = 38) Barostim Clinical evidence report (unpublished)
Probability of serious adverse event (Months 1 to 6) 0.033 0–0.05 Beta (α = 1; β = 29) Hoppe 2012 [36]
RR for mortality in Barostim arm 0.61 0.52–0.70 Log-normal (SElog = 0.0467) Application of the data from the MAGGIC risk prediction model to the individual patient data from the RCT of Barostim in heart failure
RR for hospitalizations due to heart failure in Barostim arm 0.40 0.34–1.05 Log-normal (SElog = 0.18) Zile 2015 [18]